| scholarly article | Q13442814 |
| P50 | author | Christian Hartinger | Q21964885 |
| Wolfgang Kandioller | Q59830475 | ||
| Anna K Bytzek | Q114365999 | ||
| Michael A. Jakupec | Q38800373 | ||
| Bernhard K. Keppler | Q38800395 | ||
| Iztok Turel | Q42703529 | ||
| P2093 | author name string | Jakob Kljun | |
| Caroline Bartel | |||
| P2860 | cites work | Nickel-quinolones interaction. Part 2--interaction of nickel(II) with the antibacterial drug oxolinic acid | Q43235525 |
| Influence of copper(II) and magnesium(II) ions on the ciprofloxacin binding to DNA. | Q44530744 | ||
| Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer | Q44862515 | ||
| A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. | Q44918007 | ||
| The serum protein binding of pharmacologically active gallium(III) compounds assessed by hyphenated CE-MS techniques. | Q45924256 | ||
| Modulation of the biological properties of aspirin by formation of a bioorganometallic derivative | Q46179714 | ||
| The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways | Q46505331 | ||
| Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs | Q46964649 | ||
| The influence of electroporation on cytotoxicity of anticancer ruthenium(III) complex KP1339 in vitro and in vivo. | Q51772605 | ||
| Synthesis, characterization and DNA binding of magnesium-ciprofloxacin (cfH) complex [Mg(cf)2] * 2.5H2O. | Q53526854 | ||
| Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. | Q53881839 | ||
| Osmium(II) and Ruthenium(II) Arene Maltolato Complexes: Rapid Hydrolysis and Nucleobase Binding | Q59986441 | ||
| Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-clinical Development | Q60212669 | ||
| Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice | Q60237772 | ||
| DNA interactions of dinuclear RuII arene antitumor complexes in cell-free media | Q60240455 | ||
| DNA Interactions of pH-Sensitive, Antitumor Bis(aminoalcohol)dichloroplatinum(II) Complexes†,‡ | Q60240476 | ||
| Ferrocifens and Ferrocifenols as New Potential Weapons against Breast Cancer | Q60453183 | ||
| X-Ray crystallographic, NMR and antimicrobial activity studies of magnesium complexes of fluoroquinolones – racemic ofloxacin and its S-form, levofloxacin | Q64033193 | ||
| Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity | Q67848095 | ||
| Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics | Q70892812 | ||
| The quinobenzoxazines: relationship between DNA binding and biological activity | Q73679296 | ||
| Preclinical activity of trans-indazolium[tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells | Q74620757 | ||
| A short history of SHELX | Q25938995 | ||
| Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance | Q27664216 | ||
| Ruthenium half-sandwich complexes bound to protein kinase Pim-1 | Q28289066 | ||
| Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents | Q28306539 | ||
| Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds | Q31140294 | ||
| Electrochemotherapy in treatment of tumours. | Q34004997 | ||
| Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts | Q34119399 | ||
| Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms. | Q34168916 | ||
| From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). | Q34511975 | ||
| Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. | Q36505391 | ||
| Resistance against novel anticancer metal compounds: differences and similarities | Q37131425 | ||
| Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. | Q37246984 | ||
| KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients | Q37313183 | ||
| Bioorganometallic chemistry--from teaching paradigms to medicinal applications | Q37377528 | ||
| Efficient, Mg(2+)-dependent photochemical DNA cleavage by the antitumor quinobenzoxazine (S)-A-62176. | Q38309080 | ||
| Characterization of ciprofloxacin binding to the linear single- and double-stranded DNA. | Q38352023 | ||
| Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter? | Q39668334 | ||
| Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro | Q39788647 | ||
| Synthesis and Characterization of Novel Ruthenium(III) Complexes with Histamine | Q39856936 | ||
| Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma | Q40086077 | ||
| Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro | Q40113266 | ||
| Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms | Q40147780 | ||
| Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and anti | Q40150994 | ||
| In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes | Q40412362 | ||
| Inhibition of cancer cell growth by ruthenium(II) arene complexes | Q40774119 | ||
| Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex | Q40855382 | ||
| First ruthenium organometallic complex of antibacterial agent ofloxacin. Crystal structure and interactions with DNA. | Q41367590 | ||
| P433 | issue | 9 | |
| P921 | main subject | ruthenium | Q1086 |
| quinolones | Q426549 | ||
| P304 | page(s) | 2506-2512 | |
| P577 | publication date | 2011-04-06 | |
| P1433 | published in | Organometallics | Q595719 |
| P1476 | title | Physicochemical Studies and Anticancer Potency of Ruthenium η-p-Cymene Complexes Containing Antibacterial Quinolones | |
| P478 | volume | 30 |
| Q48259223 | A general strategy to add diversity to ruthenium arene complexes with bioactive organic compounds via a coordinated (4-hydroxyphenyl)diphenylphosphine ligand |
| Q48235861 | Anti-Inflammatory Oxicams as Multi-donor Ligand Systems: pH- and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os. |
| Q62636307 | Antitumor Monoterpenes |
| Q37997361 | Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: new methodology and applications |
| Q60240403 | Cationic Ru(η6-p-cymene) Complexes of 3-Hydroxy-4-pyr(id)ones - Lipophilic Triphenylphosphine as Co-Ligand Is Key to Highly Stable and Cytotoxic Anticancer Agents |
| Q48007506 | Designing organometallic compounds for catalysis and therapy |
| Q52349456 | Exploration of selected electronic characteristics of half-sandwich organoruthenium(II) β-diketonate complexes. |
| Q92799889 | Functionalization of Ruthenium(II)(η6 -p-cymene)(3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies |
| Q50210771 | Interactions of the "piano-stool" [ruthenium(II)(η(6) -arene)(quinolone)Cl](+) complexes with water; DFT computational study. |
| Q38136881 | Metal complexes of quinolone antibiotics and their applications: an update. |
| Q38760811 | Pyrithione-based ruthenium complexes as inhibitors of aldo-keto reductase 1C enzymes and anticancer agents |
| Q38699445 | Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies. |
| Q39257995 | Self-assembled metalla-rectangles bearing azodipyridyl ligands: synthesis, characterization and antitumor activity |
| Q39000218 | Structural characterization and biological evaluation of a clioquinol-ruthenium complex with copper-independent antileukaemic activity |
| Q38946217 | Synthesis and Structural Evaluation of Organo-Ruthenium Complexes with β-Diketonates |
| Q34208154 | Synthesis, Characterization, and Antifungal Studies of Cr(III) Complex of Norfloxacin and Bipiridyl Ligand |
| Q52408881 | Synthesis, characterization and cytotoxicity of arene-ruthenium(ii) complexes with acylpyrazolones functionalized with aromatic groups in the acyl moiety. |
| Q50803523 | Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery |
Search more.